VITA 34 AG (V3V) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VITA 34 AG (V3V) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€425.00K ≈ $496.87K USD) by net assets (€5.42 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VITA 34 AG (V3V) liquidity interval to measure how many days the company can operate on defensive assets alone.
VITA 34 AG - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how VITA 34 AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
VITA 34 AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VITA 34 AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tasco Bhd
KLSE:5140
|
-0.035x |
|
Handok
KO:002390
|
-0.058x |
|
Union Auction Public Company Limited
BK:AUCT
|
-0.010x |
|
Crown Seal Public Company Limited
BK:CSC
|
0.028x |
|
Panin Sekuritas Tbk
JK:PANS
|
0.079x |
|
Kingstate Electronics
TWO:3206
|
0.095x |
|
NPC Co. Ltd
KO:004250
|
0.040x |
|
MS Autotech Co.Ltd
KQ:123040
|
0.004x |
Annual Cash Flow Conversion Efficiency for VITA 34 AG (2006–2025)
The table below shows the annual cash flow conversion efficiency of VITA 34 AG from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see VITA 34 AG (V3V) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €5.42 Million ≈ $6.33 Million |
€3.88 Million ≈ $4.53 Million |
0.716x | +6.75% |
| 2024-12-31 | €12.91 Million ≈ $15.09 Million |
€8.65 Million ≈ $10.12 Million |
0.671x | +66.85% |
| 2023-12-31 | €22.77 Million ≈ $26.63 Million |
€9.15 Million ≈ $10.70 Million |
0.402x | +242.02% |
| 2022-12-31 | €15.85 Million ≈ $18.53 Million |
€-4.49 Million ≈ $-5.24 Million |
-0.283x | -535.27% |
| 2021-12-31 | €41.94 Million ≈ $49.03 Million |
€2.73 Million ≈ $3.19 Million |
0.065x | -51.75% |
| 2020-12-31 | €29.54 Million ≈ $34.53 Million |
€3.98 Million ≈ $4.65 Million |
0.135x | -35.44% |
| 2019-12-31 | €30.27 Million ≈ $35.39 Million |
€6.32 Million ≈ $7.39 Million |
0.209x | +34.13% |
| 2018-12-31 | €29.55 Million ≈ $34.54 Million |
€4.60 Million ≈ $5.38 Million |
0.156x | +201.50% |
| 2017-12-31 | €29.64 Million ≈ $34.66 Million |
€1.53 Million ≈ $1.79 Million |
0.052x | -46.63% |
| 2016-12-31 | €23.65 Million ≈ $27.65 Million |
€2.29 Million ≈ $2.67 Million |
0.097x | -11.30% |
| 2015-12-31 | €23.76 Million ≈ $27.77 Million |
€2.59 Million ≈ $3.03 Million |
0.109x | +129.00% |
| 2014-12-31 | €22.16 Million ≈ $25.91 Million |
€1.05 Million ≈ $1.23 Million |
0.048x | -42.89% |
| 2013-12-31 | €21.29 Million ≈ $24.89 Million |
€1.77 Million ≈ $2.08 Million |
0.083x | -16.21% |
| 2012-12-31 | €20.49 Million ≈ $23.96 Million |
€2.04 Million ≈ $2.38 Million |
0.099x | +391.47% |
| 2011-12-31 | €20.01 Million ≈ $23.39 Million |
€-683.00K ≈ $-798.50K |
-0.034x | -163.72% |
| 2010-12-31 | €18.82 Million ≈ $22.00 Million |
€1.01 Million ≈ $1.18 Million |
0.054x | -12.02% |
| 2009-12-31 | €18.87 Million ≈ $22.06 Million |
€1.15 Million ≈ $1.34 Million |
0.061x | +137.50% |
| 2008-12-31 | €18.11 Million ≈ $21.17 Million |
€-2.94 Million ≈ $-3.44 Million |
-0.162x | -92.47% |
| 2007-12-31 | €19.73 Million ≈ $23.07 Million |
€-1.66 Million ≈ $-1.95 Million |
-0.084x | -219.93% |
| 2006-12-31 | €12.94 Million ≈ $15.12 Million |
€-341.00K ≈ $-398.66K |
-0.026x | -- |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more